Merck releases insomnia drug in US
February 4, 2015Sales and Marketing FDA, Merck, belsomra, insomnia, orexin, suvorexant
Merck’s insomnia drug Belsomra is now available in the US to treat patients who have difficulty falling asleep or staying …
New chairman for Bayer’s Central Works Council
February 4, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Oliver Zühlke, Thomas de Win, central works council
Oliver Zühlke has succeeded Thomas de Win as chairman at the Central Works Council of Bayer as he steps down …
Mylan buys into women’s health
February 3, 2015Sales and Marketing Abbott, FDA, India, Mylan, famy care, female, women
Mylan is to acquire a number of women’s healthcare companies from Indian-based Famy Care that will build upon its 2008 …
Boehringer and Lilly score FDA yes for Glyxambi
February 3, 2015Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin
The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …
Sucampo Pharma names new CFO
February 3, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing andrew smith, sucampo
US firm Sucampo Pharmaceuticals has appointed Andrew Smith from within its ranks to fulfill the role of chief financial officer. …
FDA fast-tracks Roche lung cancer drug
February 2, 2015Sales and Marketing Cancer, FDA, MPDL3280A, Roche, bladder, lung, oncology, pdl1
Roche will be celebrating after its investigational cancer drug MPDL3280A has been fast-tracked by the FDA for the second time. …
Takeda scraps vaccine trial in Phase II
February 2, 2015Research and Development, Sales and Marketing Diptheria-Tetanus-acellular Pertussis (DTaP) and Sabin inactivated poliovirus vaccine (sIPV), Rajeev Venkayya, TAK-361S, Takeda
Takeda has announced it is abandoning the development of a vaccine in Japan that was in Phase II clinical trials.TAK-361S, …
Sun Pharma and Ranbaxy merger gets US nod
February 2, 2015Manufacturing and Production, Sales and Marketing India, Ranbaxy, Sun Pharma, US, generics, merger, recall, torrent
The US Federal Trade Commission has given its approval for Sun Pharma’s $4 billion acquisition of troubled Indian firm Ranbaxy …
Shire drug approved for binge eating disorder
February 2, 2015Sales and Marketing ADHD, FDA, Shire, Vyvanse, binge, eating, lisdexamfetamine dimesylate, obesity
Shire has become the first company to gain FDA approval for a treatment for binge eating disorder (BED) in adults …
Stephen Whitehead: pharma has transformed
February 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, NHS, NICE, PPRS, Stephen Whitehead, lgbt, pharma
According to The Association of the British Pharmaceutical Industry (ABPI) the dominant issue in 2015 will be the affordability and …
Packer Forbes Communications hires director
February 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Packer Forbes, samantha bremner
Samantha Bremner has joined healthcare comms firm Packer Forbes as an associate director and member of the agency’s leadership team.
J&J leukaemia drug gets FDA go-ahead
January 30, 2015Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson
The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …
Government spending on Tamfilu is justified
January 30, 2015Research and Development, Sales and Marketing BMJ, Lancet, Roche, Tamiflu, alltrials, oseltamivir, transparency
The most thorough analysis of Roche’s Tamiflu to date suggests that the controversial treatment can shorten the duration of flu …
BMS wins FDA approval for HIV pill
January 30, 2015Sales and Marketing BMS, Bristol-Myers Squibb, FDA, Gilead, Reyataz, atazanavir, cobicistat), evotaz, tybost
Bristol-Myers Squibb has earned FDA approval for its HIV combination treatment Evotaz. The US drugs regulator gave BMS the go-ahead …
Patients lack data confidence in NHS
January 30, 2015Medical Communications, Sales and Marketing Astellas, NHS, care data, data, online, privacy
A recent pharma survey has found that a majority of Britons lack confidence in the NHS to keep their personal …
Google partners with Biogen on multiple sclerosis
January 30, 2015Medical Communications, Sales and Marketing Biogen, MS, calico, conrad, google, google x, scangos
Google is making further headway into healthcare by teaming up with Biogen Idec in order to study what leads to …
Gilead makes two senior promotions
January 30, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, andrew cheng
Gilead Sciences has promoted Dr Andrew Cheng to the position of executive vice president, HIV therapeutics and development operations, and …
Scientists warn Ebola virus is mutating
January 29, 2015Research and Development, Sales and Marketing Africa, Ebola, GAVI, GSK, Institut Pasteur, J&J, JJ, guinea
Researchers in France studying the Ebola epidemic say the virus has mutated making it potentially even more contagious. Scientists based …
GSK-Novartis mega-deal signed-off by EC
January 29, 2015Research and Development, Sales and Marketing Abbott, GSK, Mylan, Novartis, acquisition, etc, merger
The European Commission has approved a GSK-Novartis M&A deal, in which GSK will purchase Novartis’ vaccines unit and Novartis will …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
